Skip to main content

Table 3 Odds ratios for breast cancer according to cumulative SSRI dose during exposure time windows

From: A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: The impact of duration of use, cumulative dose and latency

Exposure time window a Total SSRI dosage b
(mg)
Cases (n = 1,701) Controls (n = 17,017) Unadjusted OR c
(95% CI)
Adjusted OR d
(95% CI)
   n (%) n (%)   
≥2 years No use e (reference) 1,442 (84.8) 14,415 (84.7) 1.00 1.00
  1 to 27, 750 mg 222 (13.1) 2,198 (12.9) 1.01 (0.87, 1.17) 1.01 (0.87, 1.17)
  ≥27, 750 mg 37 (2.2) 404 (2.4) 0.92 (0.65, 1.29) 0.91 (0.64, 1.28)
2 to 7 years No use e (reference) 1,512 (88.9) 15,122 (88.9) 1.00 1.00
  1 to 25, 365 mg 161 (9.5) 1,594 (9.4) 1.01 (0.85, 1.20) 1.01 (0.85, 1.20)
  ≥25, 365 mg 28 (1.7) 301 (1.8) 0.93 (0.63, 1.38) 0.92 (0.62, 1.36)
>7 years No use e (reference) 1,558 (91.6) 15,475 (90.9) 1.00 1.00
  1 to 20, 340 mg 118 (6.9) 1,303 (7.7) 0.90 (0.74, 1.09) 0.90 (0.74, 1.09)
  ≥20, 340 mg 25 (1.5) 239 (1.4) 1.04 (0.69, 1.57) 1.02 (0.67, 1.55)
  1. OR = odds ratio; CI = confidence interval
  2. a Prior to index date.
  3. b Combined dosage calculated using fluoxetine-equivalent dosages according to the World Health Organization's defined daily doses (DDD) methodology.
  4. c Matched on age in five-year age groups but unadjusted for the influence of other risk factors.
  5. d Adjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
  6. e 'No use' (reference category) refers to women with no SSRI prescriptions dispensed during the specified time period evaluated.
  7. Note: Percentages may not add up to 100% due to rounding.